Novocuretrial.com

Novocuretrial.com has Server used 149.126.6.119 IP Address with Hostname in Switzerland. Below listing website ranking, Similar Webs, Backlinks. This domain was first 2006-11-03 (14 years, 349 days) and hosted in Switzerland, server ping response time 89 ms

DNS & Emails Contact

This tool is used to extract the DNS and Emails from this domain uses to contact the customer.

Fetching Emails ...

Extract All Emails from Domain

Top Keywords Suggestions

Keywords suggestion tool used Novocuretrial keyword to suggest some keywords related from this domain. If you want more, you can press button Load more »

1 Novocure trial

Hosting Provider

Website: Novocuretrial.com
Hostname: vsa-pavexi.cyon.net
Country:
Latitude: 47.144901275635
Longitude: 8.1550998687744
Area Code: 0
Email AbuseNo Emails Found

Find Other Domains on Any IP/ Domain


New! Domain Extensions Updated .com .org .de .net .uk   » more ...

Domains Actived Recently

   » Revo.com (4 hours ago)

   » Bobbyjonesband.com (18 hours ago)

   » 1stchoiceautosllc.com (7 hours ago)

   » Huishoubao.com (1 day ago)

   » M1file.com (4 day ago)

   » Renhomesantalya.com (2 day ago)

   » Napadrivertours.com (22 hours ago)

   » Barefootconsultants.com (4 hours ago)

Results For Websites Listing

Found 48 Websites with content related to this domain, It is result after search with search engine

Novocure Trial

Novocuretrial.com   DA: 21 PA: 21 MOZ Rank: 42

  • Novocure is the sponsor of clinical trials testing TTFields in several cancers
  • TTFields are delivered to the region of the tumor using a portable medical device for continuous, home use
  • The system applies TTFields non-invasively, and was designed to allow patients to maintain their lifestyle while receiving TTFields.

Novocure Therapy For Solid Tumors Called Tumor Treating

Novocure.com   DA: 16 PA: 16 MOZ Rank: 33

  • novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma and mesothelioma
  • Novocure has ongoing or completed clinical trials investigating our therapy in brain metastases, gastric cancer, glioblastoma, liver cancer, non …

METIS Brain Metastasis Novocure Trials

Novocuretrial.com   DA: 21 PA: 7 MOZ Rank: 30

  • The METIS trial is intended for patients who have recently been diagnosed with brain metastases from non-small cell lung cancer (NSCLC)
  • This clinical trial is evaluating the safety and efficacy of the NovoTTF-100M System for this indication, when added after the standard stereotactic radiosurgery (SRS) normally given

Effect Of Tumor Treating Fields (TTFields) (150 KHz

Clinicaltrials.gov   DA: 18 PA: 21 MOZ Rank: 42

The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-100L System, concurrent with standard therapies for stage 4 NSCLC patients, following progression while on or after platinum based treatment.The device is an experimental, portable, battery operated device for chronic administration of alternating electric

Novocure Shares Data From Post-approval Brain Cancer

Medtechdive.com   DA: 19 PA: 50 MOZ Rank: 73

  • Dive Insight: Novocure’s pivotal clinical trial failed to show Optune is superior to chemotherapy in patients with recurrent GBM, a form of brain cancer
  • However, with Optune holding its own, achieving a median overall survival of 6.6 months, FDA concluded the benefits of the device outweighed the risks, leading it to approve the product for use as a monotherapy in recurrent GBM.

FDA Approves Novocure Device To Treat Rare Lung Cancer

Medtechdive.com   DA: 19 PA: 50 MOZ Rank: 74

  • The lack of a control arm in the Novocure trial means NovoTTF-100L may have faced an inaccurately easy comparison to standard-of-care chemotherapy
  • That worry was articulated by Prasad, a hematologist-oncologist and associate professor of medicine at Oregon Health and Science University, who took to Twitter to call the authorization of NovoTTF

Investigators Test Tumor-Treating Fields In Lung Cancer

Onclive.com   DA: 15 PA: 50 MOZ Rank: 71

  • LUNAR will test the safety and efficacy of tumor-treating fields (TTFields) produced by the noninvasive NovoTTF-100L System, developed by Novocure

Glioblastoma (GBM) Treatment Optune® Official Patient Site

Optune.com   DA: 14 PA: 14 MOZ Rank: 35

  • More than 18,000 people have started Optune
  • Optune is a wearable, portable, FDA-approved treatment for glioblastoma (GBM) that works by creating Tumor Treating Fields (TTFields), which are electric fields that disrupt cancer cell division

Jobs With NovoCure Ltd.

Biospace.com   DA: 16 PA: 31 MOZ Rank: 55

  • FDA Grants Breakthrough Device Designation to the NovoTTF-200T™ System for Advanced Liver Cancer
  • 9/9/2021. Novocure (NASDAQ: NVCR) today announced the United States Food and Drug Administration (FDA) has granted breakthrough designation …

FDA Approves The NovoTTF-100A System For The Treatment Of

S21.q4cdn.com   DA: 13 PA: 50 MOZ Rank: 72

  • trial, please visit HUwww.novocuretrial.com UH
  • About Novocure Novocure Limited is a private oncology company pioneering a novel therapy for solid tumors
  • Novocure’s worldwide headquarters is located in the Jersey Isle
  • Novocure’s US operations are based in Portsmouth, NH and the company’s research center is located in Haifa, Israel.

Clinical Trials

Vitamedicalassociates.com   DA: 25 PA: 34 MOZ Rank: 69

  • Pancreatic and lung cancer clinical trials are currently open for patient enrollment at Vita Medical Associates, P.C
  • Tumor Treating Fields (TTFields) is a non-invasive regional treatment, which has been demonstrated to prolong survival in a Phase 3 study in newly diagnosed glioblastoma.

View All Jobs

Careers.novocure.com   DA: 20 PA: 13 MOZ Rank: 44

On this site, videos and images identified as Optune users, caregivers or healthcare professionals depict actual patients, caregivers and healthcare professionals.

Novocure Issues Final Phase 2 Liver Cancer Results; Plans

Marketwatch.com   DA: 19 PA: 50 MOZ Rank: 81

  • said that in final results from its Phase 2 pilot trial in liver cancer, the disease control rate for Tumor Treating Fields with sorafenib was …

SUMMARY OF SAFETY AND EFFECTIVENESS DATA (SSED) I. …

Accessdata.fda.gov   DA: 22 PA: 33 MOZ Rank: 68

  • PMA P100034/S013 Summary of Safety and Effectiveness 2 II
  • INDICATIONS FOR USE Optune™ is intended as a treatment for adult patients (22 years of age or older) with

NovoCure Limited (NVCR) Stock Forum & Discussion

Finance.yahoo.com   DA: 17 PA: 21 MOZ Rank: 52

  • Find the latest NovoCure Limited (NVCR) stock discussion in Yahoo Finance's forum
  • Share your opinion and gain insight from other stock traders and investors.

Novocure Presents Final Safety And Efficacy Results From

Finance.yahoo.com   DA: 17 PA: 50 MOZ Rank: 82

  • HELIER, Jersey, July 01, 2021--Novocure announced final safety and efficacy results from its HEPANOVA trial in liver cancer, and plans to proceed with a phase 3 pivotal trial.

Clinical Trials Chicago Medicine

Chicago.medicine.uic.edu   DA: 24 PA: 50 MOZ Rank: 90

  • ACE: An Aneurysm Coiling Efficiency Study of the Penumbra Coil 400 System
  • This study is a prospective, multi-center study of patients with intracranial aneurysms, peripheral aneurysms or other malformations who are treated by the PC 400 System

Shawn Andrews

Linkedin.com   DA: 16 PA: 17 MOZ Rank: 50

  • View Shawn Andrews’ profile on LinkedIn, the world’s largest professional community
  • Shawn has 2 jobs listed on their profile
  • See the complete profile on LinkedIn and discover Shawn’s

Successful Phase III Clinical Trial Results Reported For

Prnewswire.com   DA: 18 PA: 50 MOZ Rank: 86

CHICAGO, June 5 /PRNewswire/ -- Data from the first phase III clinical trial of NovoCure's NovoTTF device for treatment of patients with recurrent glioblastoma (GBM) were …

FDA Approves The NovoTTF-100A System For The Treatment Of

Prnewswire.com   DA: 18 PA: 50 MOZ Rank: 87

  • For additional information about this trial, please visit www.novocuretrial.com
  • About Novocure Novocure Limited is a private oncology company pioneering a novel therapy for solid tumors.

Novocure VentureRadar

Ventureradar.com   DA: 20 PA: 50 MOZ Rank: 90

  • (doing business as NovoCure) Find out more about Novocure including the VentureRadar Innovation and Growth scores, Similar Companies and more.

Studies Show Novel Device May Enhance Chemotherapy

Bio-medicine.org   DA: 20 PA: 50 MOZ Rank: 91

  • Please refer to www.novocuretrial.com or call 1 (800) 978-0265 for more information on the ongoing trial
  • The in vitro study looked at the effects of TTFields alone and in combination with DTIC, a precursor of MTIC (the active metabolite of Temozolomide) in human GBM cells.

FDA Approves First New Treatment For Mesothelioma In 15 Years

Asbestos.com   DA: 16 PA: 50 MOZ Rank: 88

  • It is the first new treatment for mesothelioma in more than 15 years that the FDA has approved
  • In 2004, the agency added the chemotherapy drug pemetrexed (Alimta) to standard-of-care treatment
  • The FDA approved Novocure’s NovoTTF-100L System under the agency’s Humanitarian Device Exemption
  • The approval comes eight months after Novocure

Andrea Armstead, PhD

Linkedin.com   DA: 16 PA: 32 MOZ Rank: 71

  • Articles by Andrea MagCloudz in the News! By Andrea Armstead, PhD Jan 19, 2016
  • Quad Technologies MagCloudz Launch!

Jobs With NovoCure Ltd. Page 5

Biospace.com   DA: 16 PA: 33 MOZ Rank: 73

  • Novocure’s Chief Science Officer Retires after 17 Years of Service
  • Novocure (NASDAQ: NVCR) today announced the retirement of Dr
  • Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development, effective May 1, 2019.

Groundbreaking Research Offers Hope For Glioblastoma

Chicago.medicine.uic.edu   DA: 24 PA: 50 MOZ Rank: 99

  • Torres continues to receive his NovoTTF treatment more than four years later
  • To enroll in this trial or to find out about other innovative research in the Department of Neurosurgery, contact Research Manager Karriem Watson at 312-355-0334 or email at [email protected]
  • For more information on the NovoTTF device, please visit www.novocuretrial.com.

Tornado Insider

Tornado-insider.com   DA: 23 PA: 19 MOZ Rank: 68

  • NovoCure initiates clinical trial for patients with newly diagnosed glioblastoma multiforme
  • The medical device company is focused on developing the Novo-TTF device, a non-invasive portable medical device for the treatment of cancer.

Novocuretrial.com Competitive Analysis, Marketing Mix And

Alexa.com   DA: 13 PA: 27 MOZ Rank: 67

  • novocuretrial.com Competitive Analysis, Marketing Mix and Traffic vs
  • endbraincancer.org novocure.com optune.com windhamvp.com Welcome to Alexa's Site Overview

NovoCure Device

Inspire.com   DA: 15 PA: 50 MOZ Rank: 93

The American Brain Tumor Association Connections Support Community connects patients, families, friends and caregivers for support and inspiration.

Recurrent Glioblastoma (GBM) Clinical Study Results Optune®

Optune.com   DA: 14 PA: 37 MOZ Rank: 80

  • The most common side effects when using Optune alone were scalp irritation (redness and itchiness) and headache
  • Other side effects were malaise, muscle twitching, fall, and skin ulcers
  • Before you start therapy with Optune, consider some of the potential benefits and side effects
  • If you have recurrent GBM, you'll use Optune alone.

Successful Phase III Clinical Trial Results Reported For

Newswise.com   DA: 16 PA: 50 MOZ Rank: 96

  • The company has clinical and pre-clinical research operations in the U.S
  • For additional information about the company, please visit www.novocuretrial.com

Keytruda And Tumor Treating Fields: New Hope For

Survivingmesothelioma.com   DA: 25 PA: 32 MOZ Rank: 88

  • Merck makes Keytruda and Tumor Treating Fields is a product of Jersey-based Novocure. Trial Will Combine Keytruda and Tumor Treating Fields
  • The first trial of this combination is for patients with PD-1 positive non-small cell lung cancer
  • The phase 2 pilot study will enroll 66 patients with advanced or metastatic NSCLC

Mesothelioma TTFields: A New Treatment For Pleural

Mesotheliomahope.com   DA: 24 PA: 39 MOZ Rank: 95

  • Mesothelioma TTFields are a cancer treatment that relies on electrical currents
  • Pads attached to a portable generator are applied to the patient’s chest
  • These pads deliver finely tuned electrical frequencies to mesothelioma tumors beneath the skin
  • The electrical currents prevent the tumors from growing and even shrink them in some cases.

Novocure Sucht Senior Project Manager, Launch Excellence

Ch.linkedin.com   DA: 15 PA: 50 MOZ Rank: 98

  • By continuing to use and navigate this website, you are agreeing to the use of cookies
  • Accept Close Skip to main content about us ABOUT US LEADERSHIP CORPORATE PRESENTATION CORPORATE TIMELINE our therapy our pipeline OUR PIPELINE CLINICAL TRIALS NOVOCURETRIAL.COM careers patient-forward investor relations INVESTOR RELATIONS PRESS RELEASES ANNUAL REPORTS …

INNOVATIVE DEVICE TO TREAT BRAIN CANCER SHOWS …

S21.q4cdn.com   DA: 13 PA: 50 MOZ Rank: 97

  • www.novocuretrial.com or by calling 800-978-0265
  • STUDY DETAILS The single-arm, pilot trial of the safety and efficacy of Novo-TTF treatment was performed on 10 patients for a total of 280 weeks
  • Efficacy analysis was performed for 10 recurrent GBM

Mesothelioma Tumor Treating Fields : Results From Stellar

Prostatecancertreatmentstage4.blogspot.com   DA: 42 PA: 48 MOZ Rank: 15

  • About Ttfields Novocure Trials from www.novocuretrial.com We did not find results for: Maybe you would like to learn more about one of these? Check spelling or type a new query
  • Check spelling or type a new query.

Studies Show Novel Device May Enhance Chemoth EurekAlert!

Eurekalert.org   DA: 18 PA: 21 MOZ Rank: 75

  • presented results yesterday evaluating the Novo-TTF device in vitro and in a pilot clinical trial that showed the device enhanced the efficacy of standard chemotherapy treatment in

NovoCure Ltd. Announces Closing Of Financing EurekAlert!

Eurekalert.org   DA: 18 PA: 21 MOZ Rank: 76

  • announced the completion of a new funding round
  • Key investors included Pfizer Inc., Johnson & Johnson Development Corporation and …

Novocure Announces FDA IDE Approval And

Businesswire.com   DA: 20 PA: 50 MOZ Rank: 12

  • FDA has approved the IDE application to initiate the KEYNOTE-B36 trial, a collaboration between Novocure and MSD in NSCLC.

Novocure Sucht Marketing Specialist EMEA In Root, Luzern

Ch.linkedin.com   DA: 15 PA: 50 MOZ Rank: 11

  • By continuing to use and navigate this website, you are agreeing to the use of cookies
  • Accept Close Skip to main content about us ABOUT US LEADERSHIP CORPORATE PRESENTATION CORPORATE TIMELINE our therapy our pipeline OUR PIPELINE CLINICAL TRIALS NOVOCURETRIAL.COM careers patient-forward investor relations INVESTOR RELATIONS PRESS RELEASES ANNUAL REPORTS …

Post Hoc Analyses Of Intention-to-Treat Population In

Sciencedirect.com   DA: 21 PA: 38 MOZ Rank: 99

  • Glioblastoma multiforme (GBM) is the most common type of primary malignant brain tumor and presents a major challenge to the neuro-oncology community
  • 1 The overall prognosis is poor with best standard care, with as few as 8%-20% of patients surviving 2 years following diagnosis 2 and less than 5% surviving beyond 5 years
  • 1 GBM is characterized by infiltrative growth and invariably recurs

NorthWest Biotherapeutics Inc. (NWBO): Somehow, Novocure

Investorshub.advfn.com   DA: 22 PA: 21 MOZ Rank: 84

  • So you first shredded Novocure trial and data into small pieces and now have cooked these pieces into dog food
  • All in all, Optune is performing below Chemo+ radiation SOC, yet is worth 16 billion
  • I think I have magic belts and vitamin D that will suit some horrible disease is …

Novocure Announces The Closing Of A Financing Round WebWire

Webwire.com   DA: 15 PA: 17 MOZ Rank: 74

NovoCure, Ltd., a privately held medical device company focused on developing the Novo-TTF device, a non-invasive portable medical device for the treatment of cancer, announced the completion of a

Alternative For Pleural Mesothelioma: Chemotherapy And

Mesotheliomahelp.org   DA: 24 PA: 50 MOZ Rank: 7

  • The key to increasing survival for mesothelioma patients is to kill the cancer cells before they can spread to other organs
  • Treatment options, including surgery, chemotherapy and radiation, all contribute to a patient’s survival, but many times the prognosis remains unchanged
  • Now, one company has turned to experimenting with delivering electromagnetic waves to the chest of pleural

Novocure Reports Data Showing TTF Therapy In Combination

Scienceblog.com   DA: 15 PA: 50 MOZ Rank: 6

  • Novocure s US operations are based in Portsmouth, NH and the company s research center is located in Haifa, Israel
  • For additional information about Novocure, please visit www.novocuretrial.com
  • EDITORS NOTE: High resolution device photos available by request.

>Beyin Tümörüne Yeni Tedavi Onaylandı: Novocure

Beyintumorutedavisi.wordpress.com   DA: 33 PA: 50 MOZ Rank: 5

  • Glioblastoma Multiforme (GBM) için geliştirilen Novocure isimli yeni tedavi sistemi Amerikan sağlık bakanlığından 3.faz deneme için onay aldı
  • Tedavi sistemi beyin tümörlerini elektrik dalgaları vererek küçültme prensibine dayanıyor
  • Elektrik dalgaları hastanın yanında gezdirebildiği taşınabilir çanta şeklinde bir cihaz

Recently Analyzed Sites

Revo.com (4 hours ago)

Bobbyjonesband.com (18 hours ago)

1stchoiceautosllc.com (7 hours ago)

Huishoubao.com (1 day ago)

M1file.com (4 day ago)

Napadrivertours.com (22 hours ago)

Trekksoft.com (4 day ago)

Tibbo.com (3 hours ago)

Wholesalegoodz.com (10 seconds ago)

Tailspinbandsc.com (12 hours ago)

Dungscanada.com (1 day ago)

Jfsorange.org (8 day ago)

Marloweslu.com (8 day ago)